To determine whether GSDMD exacerbates colitis pathology by inducing IL-18 release, we injected intraperitoneally Gsdmd-deficient mice at a concentration of 1 μg recombinant mouse IL-18 per mouse daily during DSS colitis. This evidence concerns the gene IL18 and colitis.